(VIANEWS) – DMS IMAGING (BEL 20: DMSIM.BR) shares saw an unexpected jump over 21 trading sessions, rising 33.33% from EUR0.02 to EUR0.02 at 15:16 EST on Friday despite experiencing a downward trend during its previous session. Furthermore, BEL 20 was up 0.74% to EUR3,717.19 as it continued its upward trajectory from previous trading days.
About DMS IMAGING
DMS Imaging SA, previously known as ASIT Biotech S.A, specializes in immunotherapy products to treat allergies in Belgium. Their lead product, gp-ASIT+ is currently in Phase III trial for grass pollen allergy treatment; while house dust mite allergy and peanut allergies are also being addressed with their products. DMS was founded in 1997 with its headquarters located in Liege.
Technical Analysis
DMS Imaging stock saw its volume decline significantly today, trading only 84,686 shares – representing an almost 27-11% drop from its average daily volume of 68-170 shares traded. This decline could indicate either lack of interest among investors or uncertainty on their part.
Looking at the stock’s volatility, intraday variation averaged 3.85% over the last week, month, and quarter; highest amplitude recorded last week at 3.85% and 43.22% for month 4 and quarter 3.
Technically speaking, DMS Imaging stock has been classified by the stochastic oscillator – a popular indicator used to detect overbought/oversold conditions – as oversold (20), signalling an ideal entry point for investors seeking an inexpensive investment option.
DMS Imaging stock has experienced a decline in volume and volatility, signaling potential buying opportunities for investors. Before making any definitive investment decisions however, investors should carefully evaluate additional factors like the company’s financial performance as well as overall market conditions before making decisions regarding DMS Imaging’s stock.
More news about DMS IMAGING (DMSIM.BR).
